Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs